Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - PFIZER INC | d727538d8k.htm |
| EX-1.1 - EX-1.1 - PFIZER INC | d727538dex11.htm |
| EX-5.1 - EX-5.1 - PFIZER INC | d727538dex51.htm |
| EX-4.2 - EX-4.2 - PFIZER INC | d727538dex42.htm |
| EX-99.1 - EX-99.1 - PFIZER INC | d727538dex991.htm |
Exhibit 1.2
PRICING AGREEMENT
May 12, 2014
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
One Bryant Park
New York, New York 10036
Barclays Capital Inc.
745 Seventh Avenue
New York, New York 10019
Deutsche Bank Securities Inc.
60 Wall Street
New York, New York 10005
J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
As Representatives of the several Underwriters
Ladies and Gentlemen:
Pfizer Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein and in the Underwriting Agreement, dated May 12, 2014 (the “Underwriting Agreement”), between the Company and the Representatives of the several Underwriters to issue and sell to each of the Underwriters named in Schedule I hereto (the “Underwriters”) the Securities specified in Schedule II hereto (the “Designated Securities”). Each of the provisions of the Underwriting Agreement is incorporated herein by reference in its entirety, and shall be deemed to be a part of this Agreement to the same extent as if such provisions had been set forth in full herein; and each of the representations and warranties set forth therein shall be deemed to have been made at and as of the date of this Pricing Agreement, except that each representation and warranty which refers to the Prospectus in Section 2 of the Underwriting Agreement shall be deemed to be a representation or warranty as of the date of the Underwriting Agreement in relation to the Prospectus (as therein defined), and also a representation and warranty as of the Applicable Time in relation to the Pricing Disclosure Package and Prospectus as amended or supplemented relating to the Designated Securities which are the subject of this Pricing Agreement. Each reference to the Representatives herein and in the provisions of the Underwriting Agreement so incorporated by reference shall be deemed to refer to you. Unless otherwise defined herein, terms defined in the Underwriting Agreement are used herein as therein defined. The Representatives
designated to act on behalf of the Representatives and on behalf of each of the Underwriters of the Designated Securities pursuant to Section 12 of the Underwriting Agreement and the address of the Representatives referred to in such Section 12 are set forth at the end of Schedule II hereto.
An amendment to the Registration Statement, or a supplement to the Prospectus, as the case may be, relating to the Designated Securities, in the form heretofore delivered to you is now proposed to be filed with the Commission.
Subject to the terms and conditions set forth herein and in the Underwriting Agreement incorporated herein by reference, the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at the time and place and at the purchase price to the Underwriters set forth in Schedule II hereto, the principal amount of Designated Securities set forth opposite the name of such Underwriter in Schedule I hereto, plus any additional principal amount of Designated Securities which such Underwriter may become obligated to purchase pursuant to the provisions of Section 9 of the Underwriting Agreement.
If the foregoing is in accordance with your understanding, please sign and return to us five counterparts hereof, and upon acceptance hereof by you, on behalf of each of the Underwriters this letter and such acceptance hereof, including the provisions of the Underwriting Agreement incorporated herein by reference, shall constitute a binding agreement between each of the Underwriters and the Company. It is understood that your acceptance of this letter on behalf of each of the Underwriters is or will be pursuant to the authority set forth in an Agreement among Underwriters, the form of which shall be submitted to the Company for examination upon request, but without warranty on the part of the Representatives as to the authority of the signers thereof.
[Signatures follow]
2
| Very truly yours, | ||||
| PFIZER INC. | ||||
| By: | /s/ Brian Byala | |||
| Name: | Brian Byala | |||
| Title: | Senior Vice President and Treasurer | |||
Accepted as of the date hereof:
| MERRILL LYNCH, PIERCE, FENNER & SMITH | ||||
| INCORPORATED, as a Representative of the Underwriters | ||||
| By: | /s/ Douglas Muller | |||
| Name: | Douglas Muller | |||
| Title: | Managing Director | |||
| BARCLAYS CAPITAL INC., as a Representative of the Underwriters | ||||
| By: | /s/ Pamela Kendall | |||
| Name: | Pamela Kendall | |||
| Title: | Director | |||
| DEUTSCHE BANK SECURITIES INC., as a Representative of the Underwriters | ||||
| By: | /s/ John C. McCabe | |||
| Name: | John C. McCabe | |||
| Title: | Director | |||
| By: | /s/ R. Scott Flieger | |||
| Name: | R. Scott Flieger | |||
| Title: | Managing Director | |||
| J.P. MORGAN SECURITIES LLC, as a Representative of the Underwriters | ||||
| By: | /s/ Maria Sramek | |||
| Name: | Maria Sramek | |||
| Title: | Executive Director | |||
SCHEDULE I
| Underwriters |
Principal Amount of 2017 Notes |
Principal Amount of 2019 Notes |
Principal Amount of 2024 Notes |
Principal Amount of 2044 Notes |
Principal Amount of Floating Rate Notes |
|||||||||||||||
| Merrill Lynch, Pierce, Fenner & Smith Incorporated |
$ | 167,500,000 | $ | 251,250,000 | $ | 167,500,000 | $ | 83,750,000 | $ | 83,750,000 | ||||||||||
| Barclays Capital Inc. |
$ | 167,500,000 | $ | 251,250,000 | $ | 167,500,000 | $ | 83,750,000 | $ | 83,750,000 | ||||||||||
| Deutsche Bank Securities Inc. |
$ | 167,500,000 | $ | 251,250,000 | $ | 167,500,000 | $ | 83,750,000 | $ | 83,750,000 | ||||||||||
| J.P. Morgan Securities LLC |
$ | 167,500,000 | $ | 251,250,000 | $ | 167,500,000 | $ | 83,750,000 | $ | 83,750,000 | ||||||||||
| BNP Paribas Securities Corp. |
$ | 70,000,000 | $ | 105,000,000 | $ | 70,000,000 | $ | 35,000,000 | $ | 35,000,000 | ||||||||||
| Credit Suisse Securities (USA) LLC |
$ | 70,000,000 | $ | 105,000,000 | $ | 70,000,000 | $ | 35,000,000 | $ | 35,000,000 | ||||||||||
| RBC Capital Markets, LLC |
$ | 70,000,000 | $ | 105,000,000 | $ | 70,000,000 | $ | 35,000,000 | $ | 35,000,000 | ||||||||||
| Citigroup Global Markets Inc. |
$ | 32,000,000 | $ | 48,000,000 | $ | 32,000,000 | $ | 16,000,000 | $ | 16,000,000 | ||||||||||
| HSBC Securities (USA) Inc. |
$ | 32,000,000 | $ | 48,000,000 | $ | 32,000,000 | $ | 16,000,000 | $ | 16,000,000 | ||||||||||
| RBS Securities Inc. |
$ | 16,000,000 | $ | 24,000,000 | $ | 16,000,000 | $ | 8,000,000 | $ | 8,000,000 | ||||||||||
| Santander Investment Securities Inc. |
$ | 16,000,000 | $ | 24,000,000 | $ | 16,000,000 | $ | 8,000,000 | $ | 8,000,000 | ||||||||||
| Drexel Hamilton, LLC |
$ | 6,000,000 | $ | 9,000,000 | $ | 6,000,000 | $ | 3,000,000 | $ | 3,000,000 | ||||||||||
| Loop Capital Markets LLC |
$ | 6,000,000 | $ | 9,000,000 | $ | 6,000,000 | $ | 3,000,000 | $ | 3,000,000 | ||||||||||
| Lebenthal & Co., LLC |
$ | 6,000,000 | $ | 9,000,000 | $ | 6,000,000 | $ | 3,000,000 | $ | 3,000,000 | ||||||||||
| The Williams Capital Group, L.P. |
$ | 6,000,000 | $ | 9,000,000 | $ | 6,000,000 | $ | 3,000,000 | $ | 3,000,000 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Total |
$ | 1,000,000,000 | $ | 1,500,000,000 | $ | 1,000,000,000 | $ | 500,000,000 | $ | 500,000,000 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
SCHEDULE II
Title of Designated Securities:
1. 100% Notes due 2017 (the “2017 Notes”)
2. 100% Notes due 2019 (the “2019 Notes”)
3. 400% Notes due 2024 (the “2024 Notes”)
4. 400% Notes due 2044 (the “2044 Notes”, and together with the 2017 Notes, the 2019 Notes and the 2024 Notes, the “Fixed Rate Notes”)
Floating Rate Notes due 2017 (the “Floating Rate Notes”)
Commission File Number of Initial Registration Statement:
333-181321
Aggregate Principal Amount:
2017 Notes: $1,000,000,000
2019 Notes: $1,500,000,000
2024 Notes: $1,000,000,000
2044 Notes: $500,000,000
Floating Rate Notes: $500,000,000
Price to Public:
2017 Notes: 99.912% of the principal amount, plus accrued interest, from May 15, 2014
2019 Notes: 99.811% of the principal amount, plus accrued interest, from May 15, 2014
2024 Notes: 99.597% of the principal amount, plus accrued interest, from May 15, 2014
2044 Notes: 99.669% of the principal amount, plus accrued interest, from May 15, 2014
Floating Rate Notes: 100.00% of the principal amount, plus accrued interest, from May 15, 2014
Purchase Price by Underwriters:
2017 Notes: 99.662% of the principal amount, plus accrued interest, from May 15, 2014
2019 Notes: 99.461% of the principal amount, plus accrued interest, from May 15, 2014
2024 Notes: 99.147% of the principal amount, plus accrued interest, from May 15, 2014
2044 Notes: 98.919% of the principal amount, plus accrued interest, from May 15, 2014
Floating Rate Notes: 99.750% of the principal amount, plus accrued interest, from May 15, 2014
Form of Designated Securities:
Book-entry only form represented by one or more global securities of each series of Notes deposited with the depositary or its designated custodian, to be made available for checking by the Representative at least twenty-four hours prior to the Time of Delivery at the office of the depositary.
Specified Funds for Payment of Purchase Price:
Wire transfer of immediately available funds.
Indenture:
Indenture dated January 30, 2001, between the Company and The Bank of New York Mellon as supplemented by the fourth supplemental indenture dated May 15, 2014 between the Company and The Bank of New York Mellon.
Maturity:
2017 Notes: May 15, 2017
2019 Notes: May 15, 2019
2024 Notes: May 15, 2024
2044 Notes: May 15, 2044
Floating Rate Notes: May 15, 2017
Interest Rate:
2017 Notes: 1.100% per annum
2019 Notes: 2.100% per annum
2024 Notes: 3.400% per annum
2044 Notes: 4.400% per annum
Floating Rate Notes: 3-month USD LIBOR +15 bps
Interest Payment Dates:
Fixed Rate Notes: May 15 and November 15 of each year, beginning November 15, 2014
Floating Rate Notes: February 15, May 15, August 15 and November 15 of each year, beginning on August 15, 2014
Record Dates:
Fixed Rate Notes: May 1 and November 1 prior to the corresponding Interest Payment Date
Floating Rate Notes: February 1, May 1, August 1 and November 1 prior to the corresponding Interest Payment Date.
Redemption Provisions:
The Fixed Rate Notes may be redeemed in whole or in part at the price(s) described in the Prospectus relating to the Notes.
The Floating Rate Notes are not redeemable prior to maturity.
Sinking Fund Provisions:
None.
Defeasance Provisions:
As described in the Basic Prospectus dated May 10, 2012.
Applicable Time:
4:11 P.M. New York City time on May 12, 2014
Issuer Free Writing Prospectuses:
Fixed Rate Notes Pricing Term Sheet dated May 12, 2014, as filed under Rule 433
Floating Rate Notes Pricing Term Sheet dated May 12, 2014, as filed under Rule 433
Recently Filed Documents for Section 2(d) of the Underwriting Agreement:
None.
Time of Delivery:
10:00 A.M. New York City time on May 15, 2014
Closing Location:
Simpson Thacher & Bartlett LLP, 425 Lexington Avenue, New York, NY 10017.
Additional Agreements of the Underwriters:
Each of the Underwriters has agreed that it will not offer, sell, or deliver any of the Designated Securities, directly or indirectly, or distribute the Prospectus or any other offering material relating to the Designated Securities, in or from any jurisdiction except under circumstances that will, to the best of the Underwriters’ knowledge and belief, result in compliance with the applicable laws and regulations and which will not impose any obligations on the Company.
Each of the Underwriters agrees to abide by the offering restrictions as set forth under the following captions in the Prospectus: “Underwriting—Notice to Prospective Investors in the European Economic Area”, “Underwriting—Notice to Prospective Investors in the United Kingdom”, “Underwriting—Notice to Prospective Investors in France”, “Underwriting—Notice to Prospective Investors in Hong Kong”, “Underwriting—Notice to Prospective Investors in Japan” and “Underwriting—Notice to Prospective Investors in Singapore”.
Contact Information for Representatives for purposes of Section 12 of the Underwriting Agreement:
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
50 Rockefeller Plaza
NY1-050-12-01
New York, NY 10020
Attention: High Grade Debt Capital Markets/Legal
Fax: 212-901-7881
Barclays Capital Inc.
745 Seventh Avenue
New York, New York 10019
Attention: Syndicate Registration
Fax: 646-834-8133
Deutsche Bank Securities Inc.
60 Wall Street
New York, New York 10005
Attention: Debt Capital Markets Syndicate
Fax: 212-797-4877
J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
Attention: High Grade Syndicate Desk
Fax: 212-834-4533
Information furnished by the Underwriters for purposes of Sections 2(b), 2(c), 2(d), 2(e), 8(a), 8(b) and 16(c) of the Underwriting Agreement:
The information in the last paragraph of the cover page of the Prospectus.
The information set forth in the third, fourth and ninth paragraphs under the caption “Underwriting”.
The information in the third sentence of the tenth paragraph and the second sentence of the thirteenth paragraph under the caption “Underwriting”.
No other information in the Prospectus has been furnished by the Underwriters for use therein